← Back to Analyst Consensus 
MNPR Buy
Monopar Therapeutics
Current Price —
Implied Upside —
Analysts 19
30-Day Momentum
▲ 0 upgrades / ▼ 0 downgrades / 0 reiterations from 0 firms
Next Earnings
Nov 11, 2026 (16 days)
Rating Timeline
| Date ▼ | Firm | Action | From → To Rating | Price Target | Firm Rating |
|---|---|---|---|---|---|
| Sep 11, 2026 | Barclays | maintain | Overweight → Overweight | — | 53% |
| Aug 13, 2026 | Barclays | maintain | Overweight → Overweight | — | 53% |
| Aug 13, 2026 | Cantor Fitzgerald | downgrade | Overweight → Neutral | — | 50% |
| Aug 12, 2026 | BTIG | maintain | Buy → Buy | — | 52% |
| Jul 22, 2026 | HC Wainwright & Co. | maintain | Buy → Buy | — | 44% |
| Jun 30, 2026 | BTIG | maintain | Buy → Buy | — | 52% |
| Jun 29, 2026 | HC Wainwright & Co. | reiterate | Buy → Buy | — | 44% |
| Mar 30, 2026 | Chardan Capital | maintain | Buy → Buy | — | 47% |
| Feb 23, 2026 | BTIG | reiterate | Buy → Buy | $104 | 52% |
| Feb 2, 2026 | BTIG | reiterate | Buy → Buy | $104 | 52% |
| Jan 29, 2026 | Chardan Capital | maintain | Buy → Buy | $100 | 47% |
| Jan 14, 2026 | BTIG | reiterate | Buy → Buy | $104 | 52% |
| Jan 9, 2026 | Morgan Stanley | initiate | — → Overweight | $115 | 54% |
| Nov 14, 2025 | Raymond James | downgrade | Strong Buy → Outperform | $123 | 54% |
| Nov 13, 2025 | Chardan Capital | maintain | Buy → Buy | $100 | 47% |
| Nov 10, 2025 | Leerink Partners | initiate | — → Outperform | $115 | 50% |
| Nov 9, 2025 | Chardan Capital | maintain | Buy → Buy | $100 | 47% |
| Oct 13, 2025 | Barclays | initiate | — → Overweight | $125 | 53% |
| Oct 6, 2025 | Raymond James | maintain | Strong Buy → Strong Buy | $142 | 54% |
| Oct 2, 2025 | Oppenheimer | maintain | Outperform → Outperform | $115 | 52% |
| Sep 29, 2025 | HC Wainwright & Co. | maintain | Buy → Buy | $105 | 44% |
| Sep 25, 2025 | Piper Sandler | maintain | Overweight → Overweight | $95 | 54% |
| Sep 25, 2025 | BTIG | maintain | Buy → Buy | $104 | 52% |
| Sep 25, 2025 | Chardan Capital | maintain | Buy → Buy | $85 | 47% |
| Sep 23, 2025 | Lake Street | initiate | — → Buy | $106 | 47% |
| Sep 16, 2025 | Chardan Capital | maintain | Buy → Buy | $60 | 47% |
| Sep 15, 2025 | BTIG | reiterate | Buy → Buy | $87 | 52% |
| Sep 9, 2025 | BTIG | initiate | — → Buy | $87 | 52% |
| Sep 3, 2025 | Raymond James | initiate | — → Strong Buy | $80 | 54% |
| Sep 3, 2025 | Oppenheimer | initiate | — → Outperform | $77 | 52% |
| Aug 27, 2025 | Cantor Fitzgerald | reiterate | Overweight → Overweight | $74 | 50% |
| Aug 13, 2025 | Chardan Capital | maintain | Buy → Buy | $60 | 47% |
| Jul 7, 2025 | Cantor Fitzgerald | initiate | — → Overweight | $74 | 50% |
| Apr 2, 2025 | Jones Trading | downgrade | Buy → Hold | $0 | 50% |
| Apr 1, 2025 | HC Wainwright & Co. | reiterate | Buy → Buy | $40 | 44% |
| Jan 22, 2025 | HC Wainwright & Co. | maintain | Buy → Buy | $40 | 44% |
| Jan 10, 2025 | Piper Sandler | initiate | — → Overweight | $72 | 54% |
| Nov 11, 2024 | HC Wainwright & Co. | maintain | Buy → Buy | $22 | 44% |
| Aug 14, 2024 | HC Wainwright & Co. | maintain | Buy → Buy | $6 | 44% |
| May 10, 2024 | HC Wainwright & Co. | reiterate | Buy → Buy | $2 | 44% |
| Apr 11, 2024 | JonesTrading | upgrade | Hold → Buy | $2 | 75% |
| Jun 1, 2023 | HC Wainwright & Co. | reiterate | — → Buy | $17 | 44% |
| May 15, 2023 | HC Wainwright & Co. | maintain | Buy → Buy | $2 | 44% |
| Mar 29, 2023 | Maxim Group | downgrade | Buy → Hold | $0 | 42% |
| Mar 28, 2023 | EF Hutton | maintain | — → Buy | $17 | 30% |
| Mar 24, 2023 | EF Hutton | reiterate | — → Buy | $24 | 30% |
| Feb 15, 2023 | HC Wainwright & Co. | maintain | — → Buy | $6 | 44% |
| Feb 14, 2023 | EF Hutton | reiterate | — → Buy | $24 | 30% |
| Jan 23, 2023 | EF Hutton | initiate | — → Buy | $24 | 30% |
| Aug 16, 2022 | HC Wainwright & Co. | maintain | — → Buy | $6 | 44% |
Price Target Trend
May 14, 2026 Latest: $129.92 Oct 25, 2026
EPS Estimates
+1q $-1.13
Lo: $-2.77 Hi: $-0.43
10 analysts ▲1
0y $-3.04
Lo: $-5.25 Hi: $-1.88
10 analysts ▲4
+1y $-1.92
Lo: $-5.30 Hi: $7.11
8 analysts ▲1
0q $-0.85
Lo: $-1.37 Hi: $-0.37
10 analysts ▲1
Cross-Platform Signals
No cross-platform signals in the last 90 days